Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis

Author： Bonafede Machaon   Joseph George J.   Princic Nicole   Harrison David J.  

Publisher： Informa Healthcare

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.16, Iss.9, 2013-09, pp. : 1120-1128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis

By Confavreux C.   Chapurlat R.  

Osteoporosis International, Vol. 22, Iss. 4, 2011-04 ,pp. : 1023-1036

Springer Publishing Company

Access to resources Recommend Favorite

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis

By Haberhauer Guenther  

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 9-10, 2010-05 ,pp. : 220-224

Springer Publishing Company

Access to resources Recommend Favorite

Refining a Claims‐based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 172-180

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors Affecting the Sexual Satisfaction of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

By Akkuş Yeliz  

Sexuality and Disability, Vol. 28, Iss. 4, 2010-12 ,pp. : 223-232

Springer Publishing Company

Access to resources Recommend Favorite

Biologic Response Modifiers and Pediatric Psoriasis

By  

PEDIATRIC DERMATOLOGY, Vol. 32, Iss. 3, 2015-05 ,pp. : 303-320

John Wiley & Sons Inc

Access to resources Recommend Favorite